Madrigal Pharmaceuticals (MDGL)

• Market cap: $13.4B
• 1 day: 0.7%
• 5 days: 6.79%
• 1 month: 35.86%
• 3 months: 43.62%
• 6 months: 118.01%
• Year to date: 88.68%
• 1 year: 71.52%
• 5 years: 428.89%
• 10 years: 3,607.2%
• Sector: Healthcare
• Industry: Biotechnology

About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Employees: 528